Full-Time
Manager – Medical Communications and Content Solutions
Mccs
Posted on 12/13/2025
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
No salary listed
Remote in India
Remote
 Medical, Clinical & Veterinary (1) |
|---|
- Advanced scientific doctoral degree, (eg, PhD, PharmD, MBBS/MD, MSc, MPH, MPharm)
- Excellent scientific writing skills, including an ability to interpret and summarize complicated data effectively, concisely, and persuasively.
- Minimum of 3 years of experience in writing/developing medical content for the pharmaceutical industry, academic settings, CRO, or biotech company
- Ability to lead and execute a project end-to-end
- Strong interpersonal skills to quickly build rapport and credibility with authors and key external stakeholders cross culturally/regionally to drive solutions ahead.
- Strong organizational skills and ability to prioritize multiple projects and meet deadlines with strong attention to detail and follow-up with collaborators on a regular basis. Strong understanding of statistical principles used in medical research and familiarity with epidemiologic principles
- Effective English verbal and written communication with flexibility to be clear, consistent, compliant, and appropriate for a variety of settings.
- Demonstrated ability to lead projects independently and engage diverse stakeholders.
- Understand the applications of technology to medical content development.
- The Manager will develop all relevant medical affairs content, including abstracts, manuscripts, congress posters/presentations, graphical abstracts, systematic literature reviews, plain language summaries, slide decks, medical education resources, social media, infographics, video, multi-media and other types of external-facing medical content.
- Development of drafts includes researching, organizing, compiling, interpreting and quality check of various types of technical and/or medical information for straightforward projects with internal review support.
- Collaborate with the support of a more experienced colleague with cross-functional partners including medical communications & content teams, scientific publication committee teams, congress working teams, digital channel content teams and generative AI working groups to develop medical content across assigned therapeutic areas/medicines.
- With the support of a more experienced colleague, provide solutions to authors for assigned projects and collaborate with other teams to drive these solutions (Graphics, Compliance agency, Statistics teams, Gen AI, etc.).
- Responsible for accuracy review and data quality control of all medical content to ensure that data is objectively and accurately represented.
- Ensure delivery of all projects within expected timelines while adhering to all quality and compliance requirements for medical content.
- Support more experienced colleagues in the development of training materials for product/therapeutic area priorities.
- Ensure training on relevant tools and processes, including new generative AI technology platforms, that ensure efficient and compliant execution of all medical affairs content.
- Track the progress of all assigned projects and resolve any issues/problems with guidance from the Team Lead.
- Stay abreast of evolving trends with medical content generation to ensure industry best practices are continuously leveraged.
- Train and develop expertise in industry leading tool/skill for content creation. Ensure knowledge transfer with the broader MCCS team
- Experience in creating and developing medical content
- Expertise in assigned therapeutic areas
- ISMPP-CMPP®
- Multimedia and omnichannel experience
- Rapid adoption of new digital content, technology, and resources
- Prior global exposure in professional/education settings
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Simplify's Take
What believers are saying
- Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
- VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
- ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.
What critics are saying
- Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
- Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
- Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.
What makes Pfizer unique
- Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
- Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
- Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Company News
ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich
Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.
Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.
Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.
Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.